| Literature DB >> 17266750 |
Nathalie L van der Mee-Marquet1.
Abstract
We have developed a two-step procedure for preparing the skin before peripheral venous catheter (PVC) insertions. This procedure involves two successive swabbings with wipes soaked in alcoholic antiseptic. We investigated whether this two-step procedure was as effective and safe as the standard four-step procedure--washing with detergent, rinsing, drying, applying antiseptic--by carrying out a multicentre randomised equivalence study comparing the frequency of precursor signs of infection at the site of insertion for the two skin preparation procedures. The study was carried out over an eight-month period, and 248 PVC insertion sites were evaluated. The two-step procedure was used for 130 subjects and the standard procedure for 118. Taking into account all the confounding factors predisposing patients to the complications studied, the characteristics of the two groups of patients were found to be similar, with no significant differences noted. The incidence of precursor signs of infection was 11% 24 hours after PVC insertion (27/248), 25% at 48 hours (50/203) and at 29% at 72 hours (34/119). Eleven patients had complications necessitating the withdrawal of the PVC: sensitivity of the insertion site, with redness and/or slight swelling and/or a palpable venous cord. No major complications were observed in this study. The frequency of local complications associated with PVCs reported in this study, whether simple or severe, was not affected by the skin preparation procedure used for PVC insertion (two-step or four-step procedure).Entities:
Year: 2007 PMID: 17266750 PMCID: PMC1794226 DOI: 10.1186/1471-2253-7-1
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Details of the two-step procedure (A) and the standard four-step procedure (B)
| Two-step procedure (A) | Standard four-step procedure (B) | |
| Alcoholic antiseptic solution [Bétadine® 5 % in alcohol, iodine antiseptic] | Detergent solution [Bétadine® Scrub, povidone iodine] | |
| Extensive application of the alcoholic antiseptic with sterile wipes. | Application of the foaming detergent solution. Rinsing, with sterile compresses imbibed with sterile water. |
The Maddox scale
| Index | Complications | Clinical signs |
| 0 | None | No signs |
| 1 | Simple | Sensitivity or redness at the insertion site |
| 2 | Simple | Sensitivity of the insertion site, with redness or slight swelling |
| 3 | Severe | Sensitivity of the insertion site, with redness and slight swelling or a palpable venous cord |
| 4 | Severe | Sensitivity of the insertion site, with redness, slight swelling and a palpable venous cord |
| 5 | Major | All the signs listed for index 4 plus purulence |
Characteristics of the patients of groups A and B as a function of confounding factors
| Number of patients | p* | |||
| Total | By procedure | |||
| A | B | |||
| Number of PVCs | 248 | 130 | 118 | |
| Sex ratio (M/F) | 155/93 | 84/46 | 71/47 | 0.47 |
| Age > 70 years | 88 | 42 | 46 | 0.27 |
| Immunosuppression | 62 | 32 | 30 | 0.88 |
| Insertion site | ||||
| Back of the hand | 35 | 20 | 15 | 0.91 |
| Elbow | 17 | 8 | 9 | |
| Forearm | 190 | 99 | 91 | |
| Other | 6 | 3 | 3 | |
| Nature of the PVC | ||||
| Polyurethane | 150 | 79 | 71 | 0.79 |
| Polyvinyl chloride | 57 | 28 | 29 | |
| Teflon | 41 | 23 | 18 | |
| Duration of catheterisation | ||||
| > 24 h and < 48 h | 248 | 130 | 118 | 0.87 |
| > 48 h and < 72 h | 203 | 108 | 95 | |
| 72 h | 119 | 63 | 56 | |
| Mean duration | > 48 h and < 72 h | > 48 h and < 72 h | > 48 h and < 72 h | |
| No. manipulations > 4/day | 52 | 29 | 23 | 0.58 |
| Solutes perfused | ||||
| Antibiotics | 85 | 45 | 40 | 0.90 |
| Anticancer drugs | 57 | 30 | 27 | 0.97 |
| Lipids | 9 | 5 | 4 | 0.85 |
| Blood products | 7 | 5 | 2 | 0.31 |
*Chi squared was calculated with values obtained for groups A and B.
Early signs of infection, evaluated by the Maddox index, as a function of the skin preparation procedure used
| No. of insertion site observations (%) | ||||||
| 24 hours after insertion | 48 hours after insertion | 72 hours after insertion | ||||
| By procedure | ||||||
| Maddox index | A (n = 130) | B (n = 116) | A (n = 109) | B (n = 94) | A (n = 63) | B (n = 56) |
| 0 | 112 (86%) | 107 (92%) | 81 (74%) | 72 (77%) | 44 (70%) | 41 (73%) |
| 1 Simple | 12 | 7 | 19 | 12 | 11 | 12 |
| 2 Simple | 5 | 3 | 7 | 8 | 4 | 2 |
| Total – simple | 17 (13%) | 10 (9%) | 26 (24%) | 20 (21%) | 15 (24%) | 14 (25%) |
| 3 Severe | 0 | 1 | 2 | 1 | 1 | 0 |
| 4 Severe | 1 | 0 | 0 | 1 | 3 | 1 |
| Total – severe | 1 (<1%) | 1(<1%) | 2 (2%) | 2 (2%) | 4 (6%) | 1 (2%) |
| 5 Major | 0 | 0 | 0 | 0 | 0 | 0 |
| Number of PVCs with precursor signs of infections | 18 (14%) | 9 (8%) | 28 (26%) | 22 (23%) | 19 (30%) | 15 (27%) |
| 27 (11%) | 50 (25%) | 34 (29%) | ||||
| p* | 0.127 | 0.706 | 0.684 | |||
*Chi squared was calculated for numbers of PVCs displaying precursor signs of infections in groups A and B.
Early signs of infection according to the skin preparation procedure used and the known risk factors. Number of patients (%)
| 48 hours after insertion | Maddox index 0 | Maddox index 1–2 | Maddox index 3–5 | |||
| A | B | A | B | A | B | |
| PVCs | 81 | 72 | 26 | 20 | 2 | 2 |
| Men | 51 (63) | 46 (64) | 17 (65) | 11 (55) | 2 (100) | 2 (100) |
| Age > 69 years | 28 (34) | 28 (39) | 8 (31) | 8 (40) | 1 (50) | 1 (50) |
| Immunosuppression | 20 (25) | 20 (28) | 5 (19) | 5 (25) | - | - |
| Insertion site | ||||||
| Back of the hand | 14 (17) | 9 (12) | 3 (11) | 1 (5) | - | - |
| Elbow | 5 (6) | 5 (7) | 1 (4) | 2 (10) | - | - |
| Forearm | 62 (76) | 55 (76) | 20 (77) | 17 (85) | 2 (100) | 2 (100) |
| Nature of PVC | ||||||
| Polyurethane | 52 (64) | 44 (61) | 11 (42) | 12 (60) | 2 (100) | 1 (50) |
| Polyvinyl chloride | 13 (16) | 8 (11) | 9 (35) | 4 (20) | - | 1 (50) |
| Teflon | 18 (22) | 20 (28) | 4 (15) | 4 (20) | - | - |
| Solutes perfused | ||||||
| Antibiotics | 31 (38) | 26 (36) | 9 (35) | 7 (35) | - | 2 (100) |
| Anticancer drugs | 20 (25) | 18 (25) | 4 (15) | 4 (20) | - | - |
| Lipids | 2 (2) | - | - | 2 (10) | - | - |
| Blood products | 3 (4) | - | 1 (4) | 1 (5) | - | - |
| 72 hours after insertion | Maddox index 0 | Maddox index 1–2 | Maddox index 3–5 | |||
| A | B | A | B | A | B | |
| PVCs | 44 | 41 | 15 | 14 | 4 | 1 |
| Men | 30 (68) | 28 (68) | 8 (53) | 8 (57) | 3 (75) | 1 (100) |
| Age > 69 years | 17 (39) | 15 (37) | 7 (47) | 4 (29) | 1 (25) | - |
| Immunosuppression | 12 (27) | 12 (29) | 5 (33) | 6 (43) | - | 12 (27) |
| Insertion site | ||||||
| Back of the hand | 6 (14) | 4 (10) | 4 (27) | - | 1 (25) | - |
| Elbow | 3 (7) | 3 (7) | 1 (7) | 1 (7) | - | - |
| Forearm | 34 (77) | 32 (78) | 9 (60) | 13 (93) | 3 (75) | 1 (100) |
| Nature of PVC | ||||||
| Polyurethane | 26 (59) | 23 (56) | 5 (33) | 5 (36) | 1 (25) | 1 (100) |
| Polyvinyl chloride | 8 (18) | 5 (12) | 4 (27) | 3 (21) | 3 (75) | - |
| Teflon | 11 (25) | 13 (32) | 5 (33) | 6 (43) | - | - |
| Solutes perfused | ||||||
| Antibiotics | 20 (45) | 13 (32) | 5 (33) | 3 (21) | 3 (75) | - |
| Anticancer drugs | 12 (27) | 12 (29) | 5 (33) | 5 (36) | - | - |
| Lipids | - | - | 1 (7) | 1 (7) | - | - |
| Blood products | - | - | 2 (13) | - | - | - |